LNCaP Cells

LNCaP cells, derived from a metastatic lesion in a lymph node of a prostate cancer patient, represent a critical tool in prostate cancer research, particularly for studying the role of androgens and androgen receptor (AR) dynamics in cancer progression. The LNCaP cell line is characterized by their androgen-sensitive growth and offers a window into the mechanisms underlying prostate cancer's response to hormonal manipulation. As a model for metastatic prostate cancer, parental LNCaP cells and their sublines, such as the LNCaP clone FGC, provide clinically relevant insights into disease progression, especially in the context of metastasis to bone, forming osteoblastic lesions akin to those observed in human prostate cancer. The LNCaP human prostate cancer cell line expresses a mutated form of the AR gene with broader steroid-binding specificity and therefore is pivotal for understanding the complex interplay between AR activity and prostate cancer progression. This includes the examination of AR downstream targets like PSA and NKx3.1, which are crucial for prostatic epithelial cell function. LNCaP cells are further used in cytotoxicity studies such as those induced by ripl or the potential therapeutic effects of compounds like amygdalin, within the scope of intracellular drug delivery strategies. In summary, the human prostate carcinoma cell line LNCaP serves as a cornerstone in understanding the role of androgens in cancer progression and prostate cancer, offering insights into hormone-responsive cancers, the challenges of resistant prostate cancer, and the potential for therapeutic interventions. The LNCaP cell line is considered one of the classic and most widely used human prostate cancer cell lines, alongside DU145 and PC3 cells. Prostate cancer cell lines, Prostate, Carcinoma, Growth Conditions: Adherent, clusters, Biosafety level: BSL 1